Drug Type Small molecule drug |
Synonyms Nilvadipine (JP17/USAN/INN) + [9] |
Target |
Mechanism L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (17 Jan 1989), |
Regulation- |
Molecular FormulaC19H19N3O6 |
InChIKeyFAIIFDPAEUKBEP-UHFFFAOYSA-N |
CAS Registry75530-68-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01908 | Nilvadipine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Essential Hypertension | JP | 17 Jan 1989 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | HU | 24 Apr 2013 | |
Alzheimer Disease | Preclinical | DE | 24 Apr 2013 | |
Alzheimer Disease | Preclinical | GB | 24 Apr 2013 | |
Alzheimer Disease | Preclinical | GR | 24 Apr 2013 | |
Alzheimer Disease | Preclinical | FR | 24 Apr 2013 | |
Alzheimer Disease | Preclinical | IE | 24 Apr 2013 | |
Alzheimer Disease | Preclinical | IT | 24 Apr 2013 | |
Alzheimer Disease | Preclinical | NL | 24 Apr 2013 | |
Alzheimer Disease | Preclinical | SE | 24 Apr 2013 |
Phase 3 | 511 | wyjhuvxcao(anfwgiylhv) = iaegezechv kejyvwzotk (buipslamrh, left) View more | - | 01 Aug 2019 | |||
Phase 3 | 511 | (rhcweprigp) = ckfllvcztq pvtugepwig (laqwcdcyvw, 8.09 - 10.73) View more | Negative | 24 Sep 2018 | |||
Placebo | (rhcweprigp) = vxmlajaqrv pvtugepwig (laqwcdcyvw, 8.33 - 10.93) View more | ||||||
Not Applicable | - | 9 | tdolpeksgy(elwwgevgzv) = yocfblciay jxvtdwmglk (fpyuldkjxf ) | - | 01 Apr 2010 | ||
tdolpeksgy(elwwgevgzv) = fxrnnpyhvy jxvtdwmglk (fpyuldkjxf ) |